Payment overview · 2025
General Payments
$732.33
42 reported records · 17 companies
Healthcare provider profile · identity verified
Jennifer R Wright, ANP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · KINGSPORT, TN · NPI 1689844375
Verified facts
What the public records show
CMS Open Payments records show Jennifer R Wright, ANP received $732.33 in general payments during 2025 across 42 reported records.
GlaxoSmithKline, LLC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $186.28 | 25.4% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.74 | 11.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.59 | 11.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.66 | 8.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.73 | 5.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.90 | 4.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.45 | 3.9% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $27.01 | 3.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.67 | 3.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.52 | 3.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.99 | 3.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.50 | 2.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.29 | 2.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.17 | 2.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.49 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.62 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.72 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $732.33 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $131.09 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $96.13 | 8 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $90.15 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.62 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.62 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.60 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $27.01 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| General - Female SUI Normalized: general female sui |
Device | Boston Scientific Corporation | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 19 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 97 |
| Lisinopril | Lisinopril | 543 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 439 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 89 |
| Gabapentin | Gabapentin | 396 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 331 | 46 |
| Omeprazole | Omeprazole | 319 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 72 |
| Furosemide | Furosemide | 306 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 75 |
| Trazodone Hcl | Trazodone Hcl | 248 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 245 | 37 |
| Losartan Potassium | Losartan Potassium | 245 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 242 | 41 |
| Montelukast Sodium | Montelukast Sodium | 212 | 43 |
| Potassium Chloride | Potassium Chloride | 202 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 28 |
| Sucralfate | Sucralfate | 196 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 34 |
| Famotidine | Famotidine | 186 | 31 |
| Metformin Hcl Er | Metformin Hcl | 179 | 22 |
| Bupropion Xl | Bupropion Hcl | 163 | 27 |
| Carvedilol | Carvedilol | 160 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 24 |
| Eliquis | Apixaban | 151 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 39 |
| Jardiance | Empagliflozin | 149 | 20 |
| Buspirone Hcl | Buspirone Hcl | 145 | suppressed |
| Allopurinol | Allopurinol | 141 | 20 |
| Alprazolam | Alprazolam | 141 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 20 |
| Glimepiride | Glimepiride | 132 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 127 | 26 |
| Pregabalin | Pregabalin | 124 | 16 |
| Prednisone | Prednisone | 121 | 78 |
| Metformin Hcl | Metformin Hcl | 120 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 114 | suppressed |
| Mounjaro | Tirzepatide | 114 | 19 |
| Simvastatin | Simvastatin | 114 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 27 |
| Alendronate Sodium | Alendronate Sodium | 90 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 36 |
| Sertraline Hcl | Sertraline Hcl | 88 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 23 |
| Valsartan | Valsartan | 84 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | suppressed |
| Celecoxib | Celecoxib | 72 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 12 |
| Tramadol Hcl | Tramadol Hcl | 69 | 20 |
| Ezetimibe | Ezetimibe | 68 | 12 |
| Farxiga | Dapagliflozin Propanediol | 68 | 15 |
| Januvia | Sitagliptin Phosphate | 68 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 11 |
| Ondansetron Odt | Ondansetron | 64 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 63 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | suppressed |
| Lamotrigine | Lamotrigine | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Baclofen | Baclofen | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Lovastatin | Lovastatin | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 13 |
| Fluconazole | Fluconazole | 55 | 38 |
| Cefdinir | Cefdinir | 54 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 12 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Ozempic | Semaglutide | 53 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 12 |
| Risperidone | Risperidone | 51 | suppressed |
| Trulicity | Dulaglutide | 50 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Nystatin | Nystatin | 46 | 31 |
| Azithromycin | Azithromycin | 43 | 37 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Atenolol | Atenolol | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Folic Acid | Folic Acid | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | 17 |
| Humalog | Insulin Lispro | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | 13 |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $732.33 · 42 records | GlaxoSmithKline, LLC. | AREXVY, Auvelity, CAPLYTA, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GVOKE HYPOPEN, General - Female SUI, HETLIOZ, IBSRELA, INJECTAFER, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error